Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.44 |
| ▸ | MTOR | P42345 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | STK4 | Q13043 | 4/20 | 0.41 |
| ▸ | STK3 | Q13188 | 4/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828432 | 0.83 | PDE2A (0.45) | LRRK2MTORPIK3CAPIK3CG | |
| SCHEMBL19414399 | 0.82 | FLT3 (0.44) | MTORPIK3CASTK3PIK3CG | |
| SCHEMBL13717860 | 0.80 | LRRK2 (0.51) | LRRK2STK4STK3 | |
| SCHEMBL13718282 | 0.73 | PDE3B (0.44) | LRRK2STK4STK3 | |
| SCHEMBL13718230 | 0.72 | PDE3B (0.44) | LRRK2STK4STK3 | |
| SCHEMBL13718314 | 0.72 | PDE3B (0.42) | LRRK2STK4STK3 | |
| SCHEMBL13826604 | 0.71 | LRRK2 (0.47) | LRRK2STK4STK3 | |
| SCHEMBL13717801 | 0.71 | PIK3CD (0.46) | LRRK2MTORPIK3CASTK4STK3 | |
| SCHEMBL30295802 | 0.70 | LRRK2 (0.67) | LRRK2STK4STK3 | |
| SCHEMBL13829837 | 0.70 | FLT3 (0.44) | STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | LRRK2 317/4885MTOR 76/4885PIK3CA 88/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | LRRK2 376/4885MTOR 62/4885PIK3CA 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.